Cargando…

JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells

Several signalling pathways, including the JAK/STAT signalling pathway, have been identified to regulate the differentiation of human bone marrow skeletal (mesenchymal) stem cells (hBMSCs) into bone-forming osteoblasts. Members of the JAK family mediate the intracellular signalling of various of cyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlMuraikhi, Nihal, Alaskar, Hanouf, Binhamdan, Sarah, Alotaibi, Amal, Kassem, Moustapha, Alfayez, Musaad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866227/ https://www.ncbi.nlm.nih.gov/pubmed/33503825 http://dx.doi.org/10.3390/molecules26030606

Ejemplares similares

Inhibition of GSK-3β Enhances Osteoblast Differentiation of Human Mesenchymal Stem Cells through Wnt Signalling Overexpressing Runx2
por: AlMuraikhi, Nihal, et al.
Publicado: (2023)

Tankyrase inhibitor XAV-939 enhances osteoblastogenesis and mineralization of human skeletal (mesenchymal) stem cells
por: Almasoud, Nuha, et al.
Publicado: (2020)

Author Correction: Tankyrase inhibitor XAV-939 enhances osteoblastogenesis and mineralization of human skeletal (mesenchymal) stem cells
por: Almasoud, Nuha, et al.
Publicado: (2021)

Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2019)

Notch Signaling Inhibition by LY411575 Attenuates Osteoblast Differentiation and Decreased Ectopic Bone Formation Capacity of Human Skeletal (Mesenchymal) Stem Cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2019)

Stem cell library screen identified ruxolitinib as regulator of osteoblastic differentiation of human skeletal stem cells
por: AlMuraikhi, Nihal, et al.
Publicado: (2018)

Assessment of the effect of silica calcium phosphate nanocomposite on mesenchymal stromal cell differentiation and bone regeneration in critical size defect
por: Altwaim, Shams, et al.
Publicado: (2021)

Evaluation of the regenerative potential of decellularized skeletal muscle seeded with mesenchymal stromal cells in critical-sized bone defect of rat models
por: hakeem, Lujain, et al.
Publicado: (2021)

CXCR7 signaling promotes breast cancer survival in response to mesenchymal stromal stem cell-derived factors
por: Al-toub, Mashael, et al.
Publicado: (2019)

Romidepsin Promotes Osteogenic and Adipocytic Differentiation of Human Mesenchymal Stem Cells through Inhibition of Histondeacetylase Activity
por: Ali, Dalia, et al.
Publicado: (2018)

Human osteoblasts within soft peptide hydrogels promote mineralisation in vitro
por: Castillo Diaz, Luis A, et al.
Publicado: (2014)

DP2, a Carbohydrate Derivative, Enhances In Vitro Osteoblast Mineralisation
por: Ballout, Nissrine, et al.
Publicado: (2023)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
por: Wu, Dandan, et al.
Publicado: (2020)

Extracellular ATP Released by Osteoblasts Is A Key Local Inhibitor of Bone Mineralisation
por: Orriss, Isabel R., et al.
Publicado: (2013)

Associated changes in stiffness of collagen scaffolds during osteoblast mineralisation and bone formation
por: Bakkalci, Deniz, et al.
Publicado: (2022)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1
por: Yuen, H-F, et al.
Publicado: (2010)

Strontium potently inhibits mineralisation in bone-forming primary rat osteoblast cultures and reduces numbers of osteoclasts in mouse marrow cultures
por: Wornham, D. P., et al.
Publicado: (2014)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway
por: Ruan, Hao, et al.
Publicado: (2021)

Molecular profiling of ALDH1(+) colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2018)

Prostate Cancer Cell Extracellular Vesicles Increase Mineralisation of Bone Osteoblast Precursor Cells in an In Vitro Model
por: Lanning, Ben, et al.
Publicado: (2021)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Bone morphogenetic protein 2 (BMP2) induces growth suppression and enhances chemosensitivity of human colon cancer cells
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2016)

Silver Nanoparticles Alone or in Combination with Calcium Hydroxide Modulate the Viability, Attachment, Migration, and Osteogenic Differentiation of Human Mesenchymal Stem Cells
por: Algazlan, Almaha S., et al.
Publicado: (2022)

Multiple intracellular signaling pathways orchestrate adipocytic differentiation of human bone marrow stromal stem cells
por: Ali, Dalia, et al.
Publicado: (2018)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Neoplastic Transformation of Human Mesenchymal Stromal Cells Mediated via LIN28B
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2019)

Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
por: Hamam, Rimi, et al.
Publicado: (2017)

The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures
por: Houston, D. A., et al.
Publicado: (2016)

Staphylococcus aureus protein A causes osteoblasts to hyper-mineralise in a 3D extra-cellular matrix environment
por: Kavanagh, Nicola, et al.
Publicado: (2018)

Histological Evaluation of Restylane Lyft Used as a Scaffold for Dental Pulp Regeneration in Non-Infected Immature Teeth in Dogs
por: AlHowaish, Norah A., et al.
Publicado: (2022)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
por: Chen, Yizhe, et al.
Publicado: (2022)

Meniscal mineralisation in little spotted cats
por: Rahal, Sheila C, et al.
Publicado: (2013)

Quantifying the efficiency of Hydroxyapatite Mineralising Peptides
por: Plowright, Robyn, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1qn3d4gbr3la1j32murh9phucc